Her publications help frame the distinction between investigational retatrutide research, established GLP-1-based obesity pharmacology, and the interpretation of clinical study outcomes
With forthcoming regulatory decisions and innovative formulations on the horizon, now is the time to stay informed and proactive about your treatment choices
As neurological and medical complications after stroke are not properly predicted, prevented, or dealt with, they are considered to constitute the main cause of the high morbidity and mortality associated with strokes (78)
continued approval may be contingent on verification and description of clinical benefit in a confirmatory trial
Furthermore, in a phase 2 clinical trial addressing a patient group with type 2 diabetes and overweight/obesity, after 32 weeks of treatment, the cagrisema 2.4 mg group exhibited a more significant average weight loss compared to the cagrilintide 2.4 mg group or the group using semaglutide 2.4 mg alone, with reductions of 15.6%, 8.1%, and 5.1%, respectively
Triple-hormone-receptor agonist retatrutide for obesity a phase 2 trial
